Zobrazeno 1 - 10
of 130
pro vyhledávání: '"Erika Rijavec"'
Autor:
Giuseppe L. Banna, Marcello Tiseo, Diego L. Cortinovis, Francesco Facchinetti, Joachim G. J. V. Aerts, Cinzia Baldessari, Raffaele Giusti, Emilio Bria, Francesco Grossi, Rossana Berardi, Alessandro Morabito, Annamaria Catino, Carlo Genova, Francesca Mazzoni, Alain Gelibter, Francesca Rastelli, Marianna Macerelli, Rita Chiari, Stefania Gori, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Erika Rijavec, Federica Bertolini, Federico Cappuzzo, Alessandro De Toma, Alex Friedlaender, Giulio Metro, Maria Vittoria Pensieri, Giampiero Porzio, Corrado Ficorella, David J. Pinato, Alessio Cortellini, Alfredo Addeo
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 483-488 (2022)
Abstract Background Patients with programmed cell death‐ligand 1 (PD‐L1) ≥50% metastatic non‐small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first‐line immunotherapy have heterogeneous clinical assessment
Externí odkaz:
https://doaj.org/article/c6c73bc779d045abbf30461995e450e6
Autor:
Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern
Externí odkaz:
https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b
Autor:
Carlo Genova, Roberta Tasso, Alessandra Rosa, Giovanni Rossi, Daniele Reverberi, Vincenzo Fontana, Silvia Marconi, Michela Croce, Maria Giovanna Dal Bello, Chiara Dellepiane, Marco Tagliamento, Maria Chiara Ciferri, Lodovica Zullo, Alessandro Fedeli, Angela Alama, Katia Cortese, Chiara Gentili, Eugenia Cella, Giorgia Anselmi, Marco Mora, Giulia Barletta, Erika Rijavec, Francesco Grossi, Paolo Pronzato, Simona Coco
Publikováno v:
Cells, Vol 12, Iss 6, p 832 (2023)
The treatment of non-small cell lung cancer (NSCLC) has changed dramatically with the advent of immune checkpoint inhibitors (ICIs). Despite encouraging results, their efficacy remains limited to a subgroup of patients. Circulating immune checkpoints
Externí odkaz:
https://doaj.org/article/1ae01a3f739d4d27868c612a121bdfb1
Autor:
Danilo Rocco, Alex Friedlaender, Alfredo Addeo, Marina Chiara Garassino, Diego Signorelli, Alessandro Russo, Vincenzo Sforza, Alessio Cortellini, Katia Cannita, Daniele Santini, Pietro Di Marino, Federica Zoratto, Marco Russano, Paolo Marchetti, Francesca Rastelli, Rossana Berardi, Rita Chiari, Alain Gelibter, Giampiero Porzio, Paolo Bironzo, Giuseppe L Banna, Joachim GJV Aerts, Fausto Barbieri, Diego L Cortinovis, Francesco Passiglia, Mariangela Torniai, Carlo Genova, Alessandro Inno, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Miriam G Ferrara, Lorenza Landi, Luigi Della Gravara, Serena Ricciardi, Alessandro De Toma, Vincenzo Adamo, Alessandro Leonetti, Ettore D'Argento, Erika Rijavec, Annalisa Guida, Marco Siringo, Marianna Macerelli, De Tursi Michele, Antonino Grassadonia, Alessandro Tuzi, Paola Bordi, Gabriele Minuti, Giulio Metro, Gian Paolo Spinelli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Background Some concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to progr
Externí odkaz:
https://doaj.org/article/8143f97c38ab481c9154bd8703e472e1
Autor:
Francesco Trevisani, Federico Di Marco, Matteo Floris, Antonello Pani, Roberto Minnei, Mario Scartozzi, Alessio Cirillo, Alain Gelibter, Andrea Botticelli, Erika Rijavec, Monica Cattaneo, Ornella Garrone, Michele Ghidini
Publikováno v:
Vaccines, Vol 10, Iss 5, p 679 (2022)
Immune checkpoint inhibitors (ICIs) and platinum-based chemotherapy (CT) are effective therapeutic agents for the palliative treatment of metastatic non-small-cell lung cancer (NSCLC); the aim of our study was to investigate the acute and chronic ren
Externí odkaz:
https://doaj.org/article/382c82181e8f46a9af4b64256852e076
Autor:
Selene Ottonello, Carlo Genova, Irene Cossu, Vincenzo Fontana, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Marco Tagliamento, Angela Alama, Simona Coco, Simona Boccardo, Irene Vanni, Guido Ferlazzo, Lorenzo Moretta, Francesco Grossi, Maria Cristina Mingari, Paolo Carrega, Gabriella Pietra
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical
Externí odkaz:
https://doaj.org/article/d2bc4156441047f087b7ab4cc39af254
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Publikováno v:
Pharmaceutics, Vol 13, Iss 5, p 653 (2021)
Activating mutations in RAS family proteins are found in ~25% of all human cancers. Different solid tumors are correlated with mutations in certain isoforms of RAS, with Kirsten RAS (KRAS) being the most frequently mutated isoform. Historically, KRAS
Externí odkaz:
https://doaj.org/article/8999c83508334b9b82c18e765c98afb7
Autor:
Michele Ghidini, Alice Indini, Erika Rijavec, Claudia Bareggi, Monica Cattaneo, Gianluca Tomasello, Barbara Galassi, Donatella Gambini, Francesco Grossi
Publikováno v:
Viruses, Vol 13, Iss 3, p 508 (2021)
Over the last months, as oncology specialists, we have frequently been contacted for estimating prognosis for cancer patients affected by COVID-19 infection. Until now, there have been no clear markers to guide decision making regarding the appropria
Externí odkaz:
https://doaj.org/article/78128ac587534b84b309caa3ecd406bd
Autor:
Francesco Grossi, Daryl Ramai, Barbara Galassi, Alice Indini, Erika Rijavec, Michele Ghidini, Antonio Facciorusso, Waqqas Tai, Jameel Singh
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 15:999-1007
Introduction: Cholangiocarcinoma (CCA) is a malignancy which arises from the biliary epithelium. Carcinogenesis of CCA is mainly linked to aberrant glucose metabolism and creation of an immunosuppressive environment around normal biliary epithelium.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5244103a4f9d7d93c08a36e42f12faff
https://doi.org/10.1080/17474124.2021.1946393
https://doi.org/10.1080/17474124.2021.1946393
Autor:
Francesco Grossi, Gianluca Tomasello, Erika Rijavec, Francesca Barbin, Michele Ghidini, Alice Indini, Monica Cattaneo
Publikováno v:
Expert Review of Anticancer Therapy. 21:705-713
In the last decade, immune checkpoint inhibitors have revolutionized the treatment of several malignancies including non-small cell lung cancer (NSCLC). The inhibition of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and the programmed death r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52634809ebdb3ffaa228a4ca9821241b
https://doi.org/10.1080/14737140.2021.1903322
https://doi.org/10.1080/14737140.2021.1903322